Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus Priming With BIBF 1120 BIBF 1120 Followed by Plus Paclitaxel in Breast Cancer With HER-2 Negative Correlative Proteomic Studies. and Dynamic Image.
Phase of Trial: Phase I/II
Latest Information Update: 07 Jul 2014
At a glance
- Drugs Dovitinib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- 28 Jan 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 11 Jun 2012 Additional lead trial investigator (Colomer R) added as reported by ClinicalTrials.gov.
- 23 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.